Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenues from Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three and six months ended June 30, 2016 and 2015:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Teva:
Recognition of upfront payment	$	—	$	2,908	$	—	$	5,784
Research funding		29		45		58		90
Genentech:
Recognition of upfront payment		—		181		157		360
Research funding		383		910		766		1,820
Total collaboration revenue	$	412	$	4,044	$	981	$	8,054